Costing implications of recent treatment interruption studies.
Gill
M John
MJ
Krentz
Hartmut B
HB
D023241:Antiretroviral Therapy, Highly Active / Q000191:economics*; D018791:CD4 Lymphocyte Count; D003365:Costs and Cost Analysis; D018450:Disease Progression; D015658:HIV Infections / Q000188:drug therapy / Q000191:economics*; D006801:Humans; D028761:Withholding Treatment / Q000191:economics